Losmapimod

Overview

Losmapimod (GSK-AHAB; GW856553X) is an orally active p38α/β MAPK inhibitor, with pK i values of 8.1 and 7.6 for p38α and p38β , respectively. Losmapimod reduces DUX4 expression, thus exerting efficacy in facioscapulohumeral muscular dystrophy. By inhibiting MAPK/NF-κB , Losmapimod reduces apoptosis of epileptiform hippocampal neurons, and exhibits anti-allodynia and anti-hyperalgesic activities. Losmapimod blocks the entry and fusion of Lassa fever virus ( LASV ). Losmapimod overcomes tyrosine kinase inhibitor resistance in non-small cell lung cancer (NSCLC). Losmapimod inhibits myocardial senescence and inflammation, and possesses cardioprotective activity against cardiotoxicity.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Muscle Disease | Products > Disease Areas > Viral Infection | Products > Disease Areas > Epilepsy | Products > Disease Areas > Pain | Products > Disease Areas > Heart Disease | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Facioscapulohumeral Muscular Dystrophy | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Neurological Disease | Products > Research Areas > Infection | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Arenavirus

Product Information

• Catalog No.: HY-10402
• CAS No.: 585543-15-3
• Molecular Formula: C22H26FN3O2
• Molecular Weight: 383.46
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution
• Availability: In-stock

Source

Original product source